Profiling by immunohistochemical assays using estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) classifies breast cancer into four phenotypically distinct subtypes: luminal A, luminal B, basal-like and HER2+ tumors. Here, ERBB2 is linked to breast carcinoma.